211 related articles for article (PubMed ID: 19856028)
61. [Colorectal liver metastases. Neoadjuvant chemotherapy: aspects of medical and surgical oncology].
Reinacher-Schick AC; Bechstein WO
Internist (Berl); 2007 Jan; 48(1):51-8. PubMed ID: 17160665
[TBL] [Abstract][Full Text] [Related]
62. Defined criteria for resectability improves rates of secondary resection after systemic therapy for liver limited metastatic colorectal cancer.
Jones RP; Hamann S; Malik HZ; Fenwick SW; Poston GJ; Folprecht G
Eur J Cancer; 2014 Jun; 50(9):1590-601. PubMed ID: 24661798
[TBL] [Abstract][Full Text] [Related]
63. Optimal timing of systemic therapy in resectable colorectal liver metastases.
Ihemelandu C; Levine EA; Aklilu M; Yacoub G; Howerton R; Bolemon B; Graham M; Russell G; Shen P
Am Surg; 2013 Apr; 79(4):414-21. PubMed ID: 23574853
[TBL] [Abstract][Full Text] [Related]
64. Long-term survival after liver resection for colorectal liver metastases in patients with hepatic pedicle lymph nodes involvement in the era of new chemotherapy regimens.
Oussoultzoglou E; Romain B; Panaro F; Rosso E; Pessaux P; Bachellier P; Jaeck D
Ann Surg; 2009 Jun; 249(6):879-86. PubMed ID: 19474695
[TBL] [Abstract][Full Text] [Related]
65. Effectiveness and cost-effectiveness of peri-operative versus post-operative chemotherapy for resectable colorectal liver metastases.
Ercolani G; Cucchetti A; Cescon M; Peri E; Brandi G; Del Gaudio M; Ravaioli M; Zanello M; Pinna AD
Eur J Cancer; 2011 Oct; 47(15):2291-8. PubMed ID: 21652204
[TBL] [Abstract][Full Text] [Related]
66. Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations.
Passot G; Chun YS; Kopetz SE; Overman MJ; Conrad C; Aloia TA; Vauthey JN
Eur J Surg Oncol; 2016 Sep; 42(9):1378-84. PubMed ID: 27358198
[TBL] [Abstract][Full Text] [Related]
67. Prognostic Impact of Adjuvant Chemotherapy after Hepatic Resection for Synchronous and Early Metachronous Colorectal Liver Metastases.
Nishioka Y; Moriyama J; Matoba S; Kuroyanagi H; Hashimoto M; Shindoh J
Dig Surg; 2018; 35(3):187-195. PubMed ID: 28848205
[TBL] [Abstract][Full Text] [Related]
68. Systematic review of neoadjuvant transarterial chemoembolization for resectable hepatocellular carcinoma.
Chua TC; Liauw W; Saxena A; Chu F; Glenn D; Chai A; Morris DL
Liver Int; 2010 Feb; 30(2):166-74. PubMed ID: 19912531
[TBL] [Abstract][Full Text] [Related]
69. [Hepatectomy for colorectal liver metastases after neoadjuvant chemotherapy].
Brouquet A; Benoist S
Bull Cancer; 2011 Jan; 98(1):11-8. PubMed ID: 21300602
[TBL] [Abstract][Full Text] [Related]
70. Eradication of Missing Liver Metastases After Fiducial Placement.
Passot G; Odisio BC; Zorzi D; Mahvash A; Gupta S; Wallace MJ; Kim BJ; Yamashita S; Conrad C; Aloia TA; Vauthey JN; Chun YS
J Gastrointest Surg; 2016 Jun; 20(6):1173-8. PubMed ID: 26791387
[TBL] [Abstract][Full Text] [Related]
71. Effect of neoadjuvant chemotherapy in patients with resectable colorectal liver metastases.
Zhu D; Zhong Y; Wei Y; Ye L; Lin Q; Ren L; Ye Q; Liu T; Xu J; Qin X
PLoS One; 2014; 9(1):e86543. PubMed ID: 24466143
[TBL] [Abstract][Full Text] [Related]
72. [Computed tomographic morphological evaluation of neoadjuvant chemotherapy. Effectiveness of the therapy for colorectal liver metastases].
Folprecht G; Weitz J; Hoffmann RT
Chirurg; 2014 Jan; 85(1):31-6. PubMed ID: 24366286
[TBL] [Abstract][Full Text] [Related]
73. Relevance of neoadjuvant and adjuvant treatment for patients with resectable liver metastases of colorectal carcinoma.
Lorenz M; Müller HH; Staib-Sebler E; Vetter G; Gog C; Petrowsky H; Köhne CH
Langenbecks Arch Surg; 1999 Aug; 384(4):328-38. PubMed ID: 10473852
[TBL] [Abstract][Full Text] [Related]
74. Neoadjuvant chemotherapy response influences outcomes in non-colorectal, non-neuroendocrine liver metastases.
Lucchese AM; Kalil AN; Ruiz A; Karam V; Ciacio O; Pittau G; Castaing D; Cherqui D; Sa Cunha A; Vibert E; Adam R
Br J Surg; 2018 Nov; 105(12):1665-1670. PubMed ID: 29893476
[TBL] [Abstract][Full Text] [Related]
75. Evaluating agreement regarding the resectability of colorectal liver metastases: a national case-based survey of hepatic surgeons.
Mohammad WM; Martel G; Mimeault R; Fairfull-Smith RJ; Auer RC; Balaa FK
HPB (Oxford); 2012 May; 14(5):291-7. PubMed ID: 22487066
[TBL] [Abstract][Full Text] [Related]
76. Pseudoadjuvant chemotherapy in resectable metastatic colorectal cancer.
Polastro L; El Hachem G; Hendlisz A
Curr Opin Oncol; 2018 Jul; 30(4):269-275. PubMed ID: 29762149
[TBL] [Abstract][Full Text] [Related]
77. Recurrent Colorectal Liver Metastases: Upfront Local Treatment versus Neoadjuvant Systemic Therapy Followed by Local Treatment (COLLISION RELAPSE): Study Protocol of a Phase III Prospective Randomized Controlled Trial.
Dijkstra M; Kuiper BI; Schulz HH; van der Lei S; Puijk RS; Vos DJW; Timmer FEF; Scheffer HJ; Buffart TE; van den Tol MP; Lissenberg-Witte BI; Swijnenburg RJ; Versteeg KS; Meijerink MR;
Cardiovasc Intervent Radiol; 2024 Feb; 47(2):253-262. PubMed ID: 37943351
[TBL] [Abstract][Full Text] [Related]
78. Current landscape of preoperative neoadjuvant therapies for initial resectable colorectal cancer liver metastasis.
Cheng XF; Zhao F; Chen D; Liu FL
World J Gastroenterol; 2024 Feb; 30(7):663-672. PubMed ID: 38515943
[TBL] [Abstract][Full Text] [Related]
79. Preoperative chemotherapy in upfront resectable colorectal liver metastases: New elements for an old dilemma?
Bernardi L; Roesel R; Aghayan DL; Majno-Hurst PE; De Dosso S; Cristaudi A
Cancer Treat Rev; 2024 Mar; 124():102696. PubMed ID: 38335813
[TBL] [Abstract][Full Text] [Related]
80. Current state of surgical treatment of liver metastases from colorectal cancer.
Grundmann RT
World J Gastrointest Surg; 2011 Dec; 3(12):183-96. PubMed ID: 22224173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
